

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT TWO DIAGNOSTIC DEVICES FOR DRY EYES OBTAINED MEDICAL DEVICE REGISTRATION CERTIFICATES

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Neotech Ltd* (高視創新科技有限公司) (“**Gaush Neotech**”), a wholly-owned subsidiary of the Company, has recently obtained the medical device registration certificates for two diagnostic devices for dry eyes, namely Gaush iDea FOS, a dry eye detector, and Gaush iDea Topo, a detector for dry eye and corneal topography.

Dry eye disease is a chronic ocular surface disease caused by various factors, with main symptoms including dryness, foreign body sensation and burning sensation in the eyes. According to the Expert Consensus on Sterily Surgery in China (2020) (《中國乾眼專家共識 (2020年)》), the incidence rate of dry eyes in China has reached 21% to 30%, which has become a common eye disease in modern society. The number of patients with dry eye disease increased from 223.9 million to 245.5 million from 2017 to 2021, with a compound annual growth rate of 2.3%. It is expected that the total number of patients with dry eye disease in China will reach 268.9 million by 2025, with a compound annual growth rate of 2.3% from 2021 to 2025, and 296.7 million by 2030, with a compound annual growth rate of 2.0% from 2025 to 2030.

The two diagnostic devices for dry eyes of Gaush Neotech can provide more comprehensive diagnosis schemes for dry eyes, in which a full set of dry eye examinations can be completed in a fast and non-invasive way. At the same time, they will also significantly improve the comfort level and data accuracy of examinations for patients. In particular:

- Gaush iDea FOS is a comprehensive, fast, quantitative and intelligent integrated analyzer of dry eye and ocular surface. It can quickly complete a dry eye examination of a single eye in 15 seconds with innovative technology, providing clinicians with a solid basis for diagnosis and treatment more efficiently.
- Gaush iDea Topo is a precise diagnostic device integrating comprehensive analysis of dry eye and ocular surface. It can provide clinicians with more parameters of ocular surface and tear film to facilitate comprehensive diagnosis and evaluation.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, July 30, 2024

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purposes only*